Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptidyl-prolyl isomerase A (CypA), commonly known as cyclophilin A, is an abundant member of the immunophilin family characterized by peptidyl-prolyl cis-trans isomerase activity, which catalyzes the interconversion of proline residues in polypeptide chains and thereby accelerates protein folding[3][5]. CypA plays key roles in protein quality control (chaperone-mediated folding), regulation of intracellular signaling pathways, transcription, cell death, immune response, and angiogenesis[1][3]. As the intracellular receptor for the immunosuppressant cyclosporine, CypA is critical in the suppression of T cell activation during organ transplantation[5]. Cyclophilin A is also implicated in pathologies including viral infection, chronic inflammation, cardiovascular disease, neurodegeneration, and cancer through both its enzymatic and signaling functions[1][3].
Cyclosporine binds to cyclophilin A, forming a complex that inhibits the phosphatase activity of calcineurin involved in T cell activation and immune response suppression[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidyl-prolyl isomerase A (CypA).